
Kenneth Locke and Ian Smith, industry leaders in Cell and Gene Therapy, join as iVexSol advisors
Select the appropriate stage below to see how iVexSol’s Intelligent Manufacturing can provide time-saving and cost-effective solutions to enable your clinical development program
iVexSol’s Intelligent Manufacturing solutions are highly scalable and designed to support you through clinical development and beyond.
We are working to eliminate human disease by developing transformative vector production technologies for cell and gene therapies
Kenneth Locke and Ian Smith, industry leaders in Cell and Gene Therapy, join as iVexSol advisors
Viral vector manufacturing and transduction processes today are lengthy and inconsistent
LEXINGTON, Mass., Jan. 4, 2022 /PRNewswire/ -- iVexSol, Inc., a lentiviral vector manufacturing company announces the appointment of Amitabha Deb, Ph.D. as Senior Vice President of Process Sciences and MS&T.
A gateway to explore a next generation stable lentiviral vector manufacturing technology
FOR IMMEDIATE RELEASE
Technology targets critical shortage of viral vectors for the rapidly
expanding field of cell and gene therapeutics
Kenneth Locke and Ian Smith, industry leaders in Cell and Gene Therapy, join as iVexSol advisors
Viral vector manufacturing and transduction processes today are lengthy and inconsistent
LEXINGTON, Mass., Jan. 4, 2022 /PRNewswire/ -- iVexSol, Inc., a lentiviral vector manufacturing company announces the appointment of Amitabha Deb, Ph.D. as Senior Vice President of Process Sciences and MS&T.
A gateway to explore a next generation stable lentiviral vector manufacturing technology
FOR IMMEDIATE RELEASE
Technology targets critical shortage of viral vectors for the rapidly
expanding field of cell and gene therapeutics